These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
6. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. Wang G; Sadar MD J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300 [TBL] [Abstract][Full Text] [Related]
7. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Taplin ME Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714 [TBL] [Abstract][Full Text] [Related]
8. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer. Fletterick RJ BJU Int; 2005 Dec; 96 Suppl 2():2-9. PubMed ID: 16359432 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Haapala K; Kuukasjärvi T; Hyytinen E; Rantala I; Helin HJ; Koivisto PA Hum Pathol; 2007 Mar; 38(3):474-8. PubMed ID: 17217995 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Taplin ME Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for prostate cancer: current status and future prospects. Miyamoto H; Messing EM; Chang C Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811 [TBL] [Abstract][Full Text] [Related]
12. Castration-resistant prostate cancer: locking up the molecular escape routes. Attar RM; Takimoto CH; Gottardis MM Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877 [TBL] [Abstract][Full Text] [Related]
13. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645 [TBL] [Abstract][Full Text] [Related]
14. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Kaarbø M; Klokk TI; Saatcioglu F Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377 [TBL] [Abstract][Full Text] [Related]
15. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. Brown RS; Edwards J; Dogan A; Payne H; Harland SJ; Bartlett JM; Masters JR J Pathol; 2002 Oct; 198(2):237-44. PubMed ID: 12237884 [TBL] [Abstract][Full Text] [Related]
16. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Bryce A; Ryan CJ Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117 [TBL] [Abstract][Full Text] [Related]
17. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222 [TBL] [Abstract][Full Text] [Related]
18. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Visakorpi T; Hyytinen E; Koivisto P; Tanner M; Keinänen R; Palmberg C; Palotie A; Tammela T; Isola J; Kallioniemi OP Nat Genet; 1995 Apr; 9(4):401-6. PubMed ID: 7795646 [TBL] [Abstract][Full Text] [Related]
20. The case for secondary hormonal therapies in the chemotherapy age. Small EJ; Ryan CJ J Urol; 2006 Dec; 176(6 Pt 2):S66-71. PubMed ID: 17084172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]